Devalued and distrusted: Can the pharmaceutical industry restore its broken image?

December 10, 2012

Devalued and Distrusted: Can the Pharmaceutical Industry Restore Its Broken Image? offers a balanced view of the role of drug discovery in improving public health.

The author, former Pfizer president John LaMattina addresses the progress that industry has made in improving its abilities to measure both risk and benefits of its new medicines, and then tackles the issue of R&D productivity -- the reasons for the drop-off, and how the industry can rehabilitate its image.

Devalued and Distrusted is intended to provide patients, physicians, regulators, and payers with an appreciation of these issues as well as the value that pharmaceutical R&D adds to society.
-end-
Devalued and Distrusted: Can the Pharmaceutical Industry Restore Its Broken Image?
December 2012, 128pp
978-1-1184-8747-1
$22.95; CAN $32.95; €24.60; £20.25

To arrange an interview with John L. LaMattina or for a review copy please contact: Michelle Martella.

About the Author

John L. LaMattina, PhD, retired as president of Pfizer Global Research and Development in 2007 where he managed more than 13,000 scientists and support professionals in the United States, Europe and Asia. Dr. LaMattina has received numerous awards including an Honorary Doctor of Science degree from the University of New Hampshire. He is the author of a number of publications including the book Drug Truths: Dispelling the Myths About Pharma R & D published by Wiley in 2008. He also is a contributor to Forbes.com with his Drug Truths blog.

"LaMattina stands out from many of the other observers of the industry." (Nature Chemistry, May 2009)

CONTENTSIntroduction

Part 1. "The 4 Secrets That Drug Companies Don't Want You to Know"

Part 2. What Has Happened to R&D Productivity?

a. Impact of Mergers

b. Impact of FDA

c. Impact of Payers

Part 3. Challenges in Key Therapeutic Areas for Improving Health

a. Cancer

b. Diseases of the Brain

c. Cardiovascular Disease

d. Diabetes

e. Bacterial Infections

Part 4. Improving R&D Output

a. View of Others

b. Personal Vision

Part 5. Restoring the Pharma Image

Part 6. Final Thoughts

About Wiley

Founded in 1807, John Wiley & Sons, Inc. has been a valued source of information and understanding for more than 200 years, helping people around the world meet their needs and fulfill their aspirations. Wiley and its acquired companies have published the works of more than 450 Nobel laureates in all categories: Literature, Economics, Physiology or Medicine, Physics, Chemistry, and Peace. Wiley is a global provider of content and content-enabled workflow solutions in areas of scientific, technical, medical, and scholarly research; professional development; and education. Our core businesses produce scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising; professional books, subscription products, certification and training services and online applications; and education content and services including integrated online teaching and learning resources for undergraduate and graduate students and lifelong learners. Wiley's global headquarters are located in Hoboken, New Jersey, with operations in the U.S., Europe, Asia, Canada, and Australia. The Company's Web site can be accessed at http://www.wiley.com. The Company is listed on the New York Stock Exchange under the symbols JWa and JWb.

Wiley

Related Drug Discovery Articles from Brightsurf:

December special issue of SLAS Discovery features 'drug discovery targeting COVID-19'
The December edition of SLAS Discovery, ''Drug Discovery Targeting COVID-19'' is a special collection assembled by Associate Editor Timothy Spicer (Scripps, FL, USA), focusing on drug discovery efforts toward the current global pandemic of COVID-19caused by the novel coronavirus, SARS-CoV-2.

New cell profiling method could speed TB drug discovery
A new cell profiling technology combines high throughput imaging and machine learning to provide a rapid, cost-effective way to determine how specific compounds act to destroy the bacterium that causes tuberculosis.

An open-access tool to accelerate drug discovery
The Chemical Checker provides processed, harmonized and ready-to-use bioactivity information on more than 1M small molecules.

New macrolactone database could aid drug discovery, research
Researchers have created a free-to-use database of 14,000 known macrolactones -- large molecules used in drug development -- which contains information about the molecular characteristics, chemical diversity and biological activities of this structural class.

Discovery of a drug to rescue winter depression-like behavior
A group of animal biologists and chemists at the Institute of Transformative Bio-Molecules (WPI-ITbM), Nagoya University, has used a chemical genomics approach to explore the underlying mechanism of winter depression-like behavior and identified a drug that rescues winter depression-like behavior in medaka fish.

Fat-fighting drug discovery
Cancer-fighting compound fights obesity and diabetes.

New cell models for ocular drug discovery
Researchers at the University of Eastern Finland have developed two new cell models that can open up new avenues for ocular drug discovery.

Machine learning's next frontier: Epigenetic drug discovery
Scientists at Sanford Burnham Prebys Medical Discovery Institute have developed a machine-learning algorithm that gleans information from microscope images -- allowing for high-throughput epigenetic drug screens that could unlock new treatments for cancer, heart disease, mental illness and more.

Discovery of how colorectal cancer drug works will help more patients
Some colorectal cancer patients with a certain gene mutation benefit from a chemotherapy drug called cetuximab, although the mechanism of how this drug worked was unknown.

Speeding up the drug discovery process to help patients
An international research team is perfecting a method to predict the potential clinical implications of new drugs before clinical trials even start.

Read More: Drug Discovery News and Drug Discovery Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.